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Abstract
Objective: To elucidate the pathophysiology of SCAD deficient patients who have a unique neurological phenotype, among
fatty acid oxidation disorders, with early developmental delay, CNS malformations, intractable seizures, myopathy and
clinical signs suggesting oxidative stress.
Methods: We studied skin fibroblast cultures from patients homozygous for ACADS common variant c.625G.A (n=10),
compound heterozygous for c.625G.A/c.319C.T (n=3) or homozygous for pathogenic c.319C.T (n=2) and c.1138C.T
(n=2) mutations compared to fibroblasts from patients with carnitine palmitoyltransferase 2 (CPT2) (n=5), mitochondrial
trifunctional protein (MTP)/long-chain L-3-hydroxyacyl-CoA dehydrogenase (LCHAD) (n=7), and medium-chain acyl-CoA
dehydrogenase (MCAD) deficiencies (n=4) and normal controls (n=9). All were exposed to 50 mM menadione at 37uC.
Additonal conditions included exposure to 39uC and/or hypoglycemia. Time to 100% cell death was confirmed with trypan
blue dye exclusion. Experiments were repeated with antioxidants (Vitamins C and E or N-acetylcysteine), Bezafibrate or
glucose and temperature rescue.
Results: The most significant risk factor for vulnerability to menadione-induced oxidative stress was the presence of a FAO
defect. SCADD fibroblasts were the most vulnerable compared to other FAO disorders and controls, and were similarly
affected, independent of genotype. Cell death was exacerbated by hyperthermia and/or hypoglycemia. Hyperthermia was a
more significant independent risk factor than hypoglycemia. Rescue significantly prolonged survival. Incubation with
antioxidants and Bezafibrate significantly increased viability of SCADD fibroblasts.
Interpretation: Vulnerability to oxidative stress likely contributes to neurotoxicity of SCADD regardless of ACADS genotype
and is significantly exacerbated by hyperthermia. We recommend rigorous temperature control in SCADD patients during
acute illness. Antioxidants and Bezafibrate may also prove instrumental in their management.
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Introduction
Cellular energy metabolism is largely sustained by mitochon-
drial b-oxidation of fatty acids when carbohydrate stores are
depleted after fasting or prolonged exercise. Whereas the clinical
presentations of long- and medium-chain fatty acid oxidation
disorders (FAODs) are primarily of hepatic or cardiac dysfunction,
short-chain acyl-CoA dehydrogenase deficiency (SCADD)
(OMIM # 201470) is predominantly neurological in presentation
with developmental delay, seizures, hypotonia and myopathy
[1,2]. Thirty-five SCAD gene (ACADS) inactivating mutations have
been described in this autosomal recessive disorder [1–3]. The
molecular phenomenon of the common ACADS variations,
c.625G.A and c.511C.T in SCADD is unique. These variations
are identified in SCADD patients, but also in various general
populations at allelic frequencies of 22%–43% and 3%–8%
respectively [4–7]. The biochemical consequences are SCAD
protein misfolding and aggregation described in in vitro mitochon-
drial import studies [8], which correlate poorly with clinical
severity. Patients with the ACADS gene spectrum may remain
asymptomatic or have muscle and neuronal toxicity. The
speculated role of additional gene and/or environmental modifiers
needs to be better understood.
We studied a girl with progressive limb-girdle myopathy, ptosis,
facial weakness and progressive external ophthalmoplegia and
features overlapping with mitochondrial Complex I deficiency
including cataracts and cardiomyopathy, confirmed to have
SCADD with homozygosity for c.319 C.T mutation [9]. As a
result of her myopathy, she became wheelchair-dependent by 5
years of age. Independent 1 year trials of a high carbohydrate/low
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Her total plasma aldehydes by GC/MS were significantly elevated
at 2997.6 nM, (controls 2041.36228.3, n=12) [10]. A compara-
ble rise was reported in complex I deficiency (3377.86595.7,
n=14). We thus instituted a trial of Vitamins C 200 mg twice a
day and E 400 IU daily. After 6 months, she had a 6-fold increase
in endurance time on sustained deltoid abduction.
This supported our speculation that increased oxidative stress is
a pathogenetic mechanism in SCADD. Mitochondria are a major
site of reactive oxygen species (ROS) production, which are
pathologic when excessive. Mitochondrial dysfunction with
increased ROS secondary to SCADD could explain the
overlapping clinical features of complex I and SCADD as seen
in our patient. The possible association between SCADD and
oxidative stress in vitro has been investigated. EMA inhibits
mitochondrial creatine kinase activity [11,12], increases lipid and
protein oxidation products, and decreases glutathione (GSH) levels
in rat cerebral cortex [13]. In human skeletal muscle, EMA
inhibits electron transport at complexes I–III and II–III [14].
Given that the respiratory chain (RC) may generate excessive
ROS from defective electron transport [15], at complex I and
Complex III [16,17], we speculate that EMA accumulation may
contribute to oxidative stress and the neurological symptoms in
SCADD patients by this mechanism. Furthermore, ROS report-
edly affects the permeability of the blood brain barrier, enhancing
neuronal vulnerability to ROS toxicity [18].
The second possible mechanism is a direct consequence of the
SCAD protein misfolding. The mitochondrial RC produces
superoxides or hydroxyl radicals (OH
2) from the interaction of
molecular oxygen with semi-quinone or -flavone species [19,20].
SCAD is an FAD-linked dehydrogenase, and a defect in SCAD
function, due to misfolding and defective interaction with
functional partners e.g. electron transfer flavoprotein (ETF), may
thus lead to the production of superoxides in proximity to sites of
semi-flavone production.
A third potential mechanism relates to cellular antioxidant
status. Oxidative stress is due to an imbalance between excessive
ROS generation and antioxidant capacity, such as superoxide
dismutase (SOD) and glutathione peroxidase activity [20–22]. The
two intracellular SOD enzymes are intramitochondrial manganese
superoxide dismutase (SOD2) and cytosolic copper zinc SOD
(SOD1). A recent proteomic analysis of mitochondria from
c.625G.A homozygous patient fibroblasts (n=4) revealed
reduced SOD2 protein and mRNA expression compared to
controls (n=6), rendering them more vulnerable to oxidative stress
[23]. Sequencing of the SOD2 gene did not demonstrate
abnormalities, suggesting possible intrinsic dysregulation of SOD2.
Therefore oxidative stress in SCADD could be the result of
associated biochemical abnormalities combined with intrinsic
antioxidant dysfunction and exogenous stressors. We plan to first
identify the selective vulnerability to oxidative stress, in vitro,i n
SCADD patient fibroblasts by exposure to menadione, a free
radical amplifier, both with and without stressors. Menadione
generates ROS through redox cycling, and has been shown to
decrease mitochondrial membrane potential and trigger cyto-
chrome c redistribution to the cytosol [22,24,25]. Multiple
redundant cell death pathways are activated by menadione, and
poly ADP ribose polymerase (PARP) plays an essential role in
mediating each of them [25]. As stressors, we have chosen
hyperthermia at 39uC, which increases SCAD protein aggregation
[8], and hypoglycemia, which limits the cellular bioenergetic
source and puts further stress on an already dysfunctional FAO
pathway. Both of these stressors are common well-recognized
exogenous triggers for catabolic crisis in FAO disorders. We will
then test the therapeutic efficacy of specific pathophysiology-based
treatment interventions.
We recognize that the extrapolation of cellular pathophysiologic
mechanisms from fibroblasts to neuronal tissue is suboptimal,
however this is generally the primary and often only patient cell
type available to study in vitro. We plan to compare the results from
SCAD deficient fibroblasts to those with medium and long-chain
ACAD deficiencies. The family of ACAD deficiencies have
similarities such as intermittent metabolic crises with hypoketotic
hypoglycemia and clinical variability. The long-chain ACAD
deficiencies present with hepatic, cardiac and skeletal muscle
symptoms and signs. Medium-chain ACAD deficiencies present
with hepatic features, whereas SCAD deficiency is primarily
neurological/neuromuscular in presentation. Based on our index
case, we plan to study the relative effect of oxidative stress in the
short-, medium-, and long-chain ACAD deficiencies at a cellular
level in order to determine whether this is a selective mechanistic
pathway that contributes to the chronic neurotoxicity in SCADD.
Materials and Methods
Ethics Statement
The Toronto Hospital for Sick Children Research Ethics Board
and the Danish Ethical Committee (M-20070150) approved the
use of anonymized patient fibroblasts for this study and waived the
need for informed consent based on a three-tier de-identification
which totally precluded any possibility of patient identification.
Patients
De-identified skin fibroblast cultures from clinically affected
pediatric patients (,18 years of age) with SCAD (n=17), MCAD
(n=4), CPT2 (n=5), MTP (n=6) and LCHAD (n=1) enzyme
deficiencies were provided by the Research Unit for Molecular
Medicine, Aarhus, Denmark and the Test Development Labora-
tory, Children’s Medical Center Dallas, Texas. The SCAD
deficient patient fibroblasts had the following genotypes; ACADS
c.1138T/1138T (n=2), c.319 T/319T (n=2), c.625A/319T
(n=3), and c.625A/625A (n=10). The MCAD deficient patient
fibroblasts had the following genotypes: ACADM c.985A.G/PTC
(premature stop codon), PTC/PTC, STOP (stop codon muta-
tion)/STOP, and missense/missense mutations. Four of the MTP
patients had the following genotypes: HADHA c.1528G.C/PTC,
HADHA c.1528G.C/missense, HADHB splice mutation/splice
mutation, and HADHB missense/PTC.
Controls
De-identified skin fibroblasts from asymptomatic individuals
within the pediatric age group were provided by the Tissue
Culture Laboratory, Toronto Hospital for Sick Children and the
Research Unit for Molecular Medicine, Denmark, who sequenced
for the ACADS c.625G.A genotype in all control fibroblasts which
included: c.[625G]+[625G] (G/G) (n=5), c.[625G]+[625A] (G/
A) (n=4) and c.[625A]+[625A] (A/A) (n=4). All controls were
homozygous for the wild-type sequence at nucleotide position 511
(c.511C).
All fibroblasts tested negative for mycoplasma.
Menadione toxicity assay
Skin fibroblasts were seeded in 24-well plates (Biosciences) with
20,000 cells per well. Fibroblasts were grown to a monolayer of
confluence in a-MEM containing 2.0 g/L of glucose and 10%
FCS at 37uC, in 5% CO2 then washed and incubated with
50 mmol/L menadione in serum-free a-MEM. Cells were
incubated in media with or without glucose, and at 37uCo ra t
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hour until 100% cell death in the SCAD deficient cells, and every
four hours until approximately 50% cell death, then every hour
until 100% cell death in the control cells. Time to 100% cell death
(in hours) was confirmed with 0.4% trypan-blue dye exclusion
(Gibco) by LM. If on examination of trypan-blue dye exclusion,
evaluation of cell death was ,100%, the experiment was repeated
until 100% death was confirmed. In order to confirm reproduc-
ibility, each experiment was performed in triplicate, on at least 8
separate occasions. The mean of these technical replicates were
used in the final statistical analysis.
Rescue
Rescue of hypoglycemia with a-MEM+glucose, and rescue of
hyperthermia by reducing incubator temperature from 39uCt o
37uC was performed at ,40% cell death in 11 SCADD fibroblast
lines (c.625A/625A (n=5), c.319T/625A (n=3), c.319T/319T
(n=2) and c.1138T/1138T (n=1)) after menadione exposure.
Time to 100% cell death was subsequently confirmed as above.
Intervention
Fibroblasts were incubated with menadione and i) antioxidant
vitamin C 0.8 mg/dL and vitamin E 0.9 mg/dL (antiO) (Sigma-
Aldrich), ii) N-acetyl-cysteine (NAC) 0.5 or 5 mM (Sigma-Aldrich),
preceded by 24 hours of pre-incubation with NAC prior to
menadione exposure or iii) Bezafibrate (B+) (Cayman Chemicals)
200 and 400 mmol/L in the SCADD fibroblasts only, preceded by
48 hours of pre-incubation with Bezafibrate.
Statistical analysis
Results are expressed as mean 6 SEM (hours). All values
underwent logarithmic transformation with subsequent confirma-
tion of normality using the D’Agostino Pearson normality test,
prior to statistical analysis with one-way ANOVA and Bonferroni’s
sub-group analysis (GraphPad Prism software). Logarithmic
transformation was performed due to unequal sample sizes
between groups. P-values ,0.05 were considered significant.
Results
Menadione toxicity assay
Fibroblast skin cultures from 17 patients with SCADD, 12 with
long-chain FAODs including CPT2 (n=5) and MTP/LCHAD
(n=7) deficiencies, 4 with MCADD, 4 reportedly asymptomatic
c.625G.A homozygotes (A/A), and 9 normal controls with
genotypes of c.625G/625G (G/G, n=5) and c.625G/625A (G/A,
n=4) were studied. In SCADD, no consistent genotype-pheno-
type correlations have been identified [8], therefore all 17 patient
cell lines of varying genotypes were included in one group. Each
cell line underwent menadione exposure with or without glucose
(hypoglycemia), and at 37uCo r3 9 uC (hyperthermia) (Fig. 1A to D,
Table S1). The most striking result was the exquisite vulnerability
of the SCADD patient fibroblasts compared to controls under
each of the 4 conditions, p,0.001 (Table S3). The long-chain
FAOD fibroblasts (CPT2/MTP) were also significantly more
vulnerable compared to controls under each of the four conditions,
p,0.05. Menadione toxicity in the CPT2/MTP patient fibroblasts
was comparable to that in the SCADD patient fibroblasts, p.0.05
(Table S3). The time to 100% death in the MCADD cell lines was
longer than in the control cells (625G/G and 625 G/A) only under
physiological conditions, p,0.05, but was not significantly
different when glucose deprivation and/or hyperthermia were
added, p.0.05. In addition, MCADD fibroblasts were not
significantly different from the 625 A/A controls under all four
experimental conditions, p.0.05 (Table S3). In comparison of the
controls, the 625G/G and 625G/A control fibroblasts (n=9) were
unexpectedly more vulnerable than the 625A/A control fibroblasts
(n=4) (Fig. 1A to D), also reaching significance only under
physiological conditions, p,0.05 (Table S3). This is concordant
with results of mitochondrial proteomics analysis which indicated
higher levels of SOD2 expression in 625A/A control fibroblasts
compared to lower SOD2 expression in 625G/G and 625G/A
control fibroblasts [23].
In comparison of the individual effects of hypoglycemia or
hyperthermia on viability in the SCADD patient fibroblasts,
hyperthermia had the more significant effect, p,0.01, compared
to hypoglycemia alone, p=0.05 (Table S2). Although adverse
conditions exacerbated vulnerability in all patient fibroblasts, the
overall net effect was the most significant for the SCADD
fibroblasts in all 4 experimental conditions, as shown by the short
survival times, compared to controls, p,0.001 (Table S3).
Figure 2 shows the results of the SCADD fibroblasts divided
into the four ACADS genotypes. There was no significant
difference between the c.625G.A homozygotes (n=10),
c.625G.A/c.319C.T compound heterozygotes (n=3) and
pathogenic c.319C.T (n=2) and c.1138C.T (n=2) homozy-
gotes, but there was a significant difference between each of the
SCADD patient groups when compared to the c.625G.A
controls, in all experimental conditions, except for c.319C.T
(n=2) which reached significance only under 39uC with and
without glucose (Fig. 2A to D, Table S4). It is intriguing that the
symptomatic common variant c.625G.A homozygous fibroblasts,
most of which have been shown to have a considerable residual
SCAD enzyme activity of approximately 50% of control [23],
were just as susceptible as the fibroblasts with pathogenic
mutations, which have residual SCAD enzyme activities of
,5%. This further supports the speculation that although the
biochemical abnormalities in SCADD may in part contribute to
the pathophysiology, there are other modifiers contributing to the
pathophysiology of the ACADS gene spectrum [5].
Rescue in SCADD fibroblasts
To simulate resuscitation in an acute catabolic crisis, SCADD
patient fibroblasts of all 4 genotypes (n=11) were rescued prior to
40% cell death (Figure S1). (i) After exposure to menadione and
hypoglycemia at 37uC (column 2), SCADD cells were rescued with
glucose which resulted in increased survival (column 3). This
approximated the survival of cells exposed to menadione at
physiological conditions (column 1), p=0.2. (ii) After exposure to
menadione at 39uC, cells were rescued by reducing the incubator
temperature to 37uC (column 5), p,0.0001. Survival also
approximated baseline (column 1). However, the net increase in
survival was 3.1-fold, p,0.0001, compared to glucose rescue of
1.5-fold, p,0.0001. (iii) After exposure to menadione with
hypoglycemia and hyperthermia, simultaneous glucose and
temperature rescue (column 8) had a more significant effect (2.9-
fold), p,0.0001, than glucose rescue alone at 39uC (1.3-fold),
p,0.0003. These results are concordant with the earlier finding
that hyperthermia more significantly affects SCADD cell viability
than hypoglycemia alone. It is striking that rescue restored survival
to the original baseline, despite the additional exposure of an
adverse factor. We can conclude that rescue at an early stage is
effective.
Interventions
Given that oxidative stress can be reduced with antioxidants, we
evaluated the effects of vitamin C 0.8 mg/dL and vitamin E
0.9 mg/dL (AO), and N-acetyl-cysteine (NAC) (0.5 and 5 mM) in
Oxidative Stress in SCAD Deficiency
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(B+) (200 and 400 mmol/L) which is a pan-peroxisome proliferator
activated receptor (PPAR) agonist reported to restore deficient
FAO rates in CPT2 and VLCAD fibroblasts [26]. We initially
evaluated the effects of Bezafibrate on the long-chain FAOD
group, with the expectation that restoration of FAO would reduce
oxidative stress. Bezafibrate has so far not been investigated in
SCADD, however, if short-chain FAO were also restored by
Bezafibrate, viability in the SCADD fibroblasts might similarly be
enhanced.
In the Bezafibrate and AO groups (Figure 3 and 4 respectively),
there was significant improvement in viability in the SCADD (up to
2.36,p ,0.0005 and 2.56,p ,0.0001 respectively) and CPT2/MTP
deficient (up to 5.86,p ,0.01 and 5.26,p ,0.0005) groups under all
Figure 1. Comparison of menadione toxicity in short-chain acyl-CoA dehydrogenase deficiency (SCADD), medium-chain acyl-CoA
dehydrogenase deficiency (MCADD), carnitine palmitoyltransferase 2 deficiency (CPT2D) and mitochondrial trifunctional protein
deficiency (MTPD)/long-chain L-3hydroxyacyl-CoA dehydrogenase deficiency patients and 625A/A controls (n=4) and 625G/A and
G/G (n=9) control data under the 4 experimental conditions. One-way ANOVA and Bonferroni’s Mutiple Comparison test compares
menadione toxicity, after logarithmic transformation to ensure Gaussian distribution. The ANOVA shows significant differences between all groups, in
all 4 experimental conditions, indicated by the error bar spanning all cell lines, p,0.0001(Table S1). The Bonferroni subgroup analyses are
summarized in Table S3, and indicated by the error bars comparing 2 cell lines. Figures 1a to d displays the significantly reduced time to 100% cell
death in the SCADD and CPT2/MTPD patient cell lines, compared to the 625A/A control and normal control (625 G/G and 625 G/A) cell lines. The
MCADD cell lines survived significantly longer than the normal control cell lines, only at physiological conditions (Table S3). Figures 1b to 1d show the
progressive reduction in survival time to 100% cell death in all cell lines, with the addition of glucose deprivation (Figure 1b), elevated temperature
(Figure 1c), or both (Figure 1d).
doi:10.1371/journal.pone.0017534.g001
Oxidative Stress in SCAD Deficiency
PLoS ONE | www.plosone.org 4 April 2011 | Volume 6 | Issue 4 | e17534four conditions (Fig 3 A–D and 4 A–D, Tables S5, S6). There was no
significant difference when Bezafibrate exposure was increased to
400 mmol/L in the SCADD cells, p.0.05. MCADD and control
fibroblasts did not show any significant response to Bezafibrate,
p.0.05 (Table S5). The MCADD cells did show significant response
to AO at 37uC with and without glucose (Table S6).
In the NAC group (Fig. 5), the response to treatment was even
more significant in the SCADD (up to 7.16,p ,0.0001) and
CPT2/MTP deficient (up to 7.26,p ,0.0005) groups (Fig. 5A–D,
Table S7). The MCADD fibroblasts also showed significant effects
with NAC under all 4 experimental conditions, p,0.05. In the
patient cells, there was no significant difference in effect between
NAC concentrations of 0.5 mM or 5 mM, p.0.05. The control
fibroblasts showed significant response under all 4 experimental
conditions to NAC 5 mmol/L, p,0.05 (Table S7).
In summary, the SCADD and CPT2/MTP deficient fibroblasts
showed a significant increase in viability with all 3 treatments.
NAC had the most significant effect. The SCADD and CPT2/
MTP fibroblasts were the most vulnerable to menadione- induced
oxidative stress, suggesting that these cell lines had higher levels of
cellular ROS. Therefore, the anti-oxidant intervention was most
significant in these groups. The response to Bezafibrate in SCADD
fibroblasts suggests there may be some restoration of short-chain
FAO by PPAR regulation of the ACADS gene, thereby reducing
the biochemical abnormalities arising from the SCAD block and
the resultant vulnerability to oxidative stress.
Figure 2. Menadione toxicity in different SCAD genotypes and controls under variable conditions. Patient fibroblasts with ACADS
1138T/T homozygous (n=2), 319T/T homozygous (n=2) and 625A/319T heterozygous (n=3) mutations and 625A/A symptomatic homozygotes
(n=10) are compared to 625A/A (n=4) and 625G/A and G/G controls (n=9) by ANOVA, as indicated by the error bar spanning all cell lines, p,0.0001.
Figures 2a to d shows that there were no significant differences in the time to 100% cell death between the 1138T/T, 319T/T, 625A/319T and 625A/A
SCADD patient cell lines. However, the patient cell line survival times were significantly reduced when compared to the 625A/A control and normal
625G/A and G/G control cell lines, except for 319T/T, which was significantly different only at 39uC (Table S4).
doi:10.1371/journal.pone.0017534.g002
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We pursued the hypothesis that SCADD patients may have
increased vulnerability to oxidative stress, based on the clinical and
biochemical features of our index case [9,10], the published
mechanisms for EMA-induced oxidative stress [11–14], the cellular
consequences of the SCAD protein misfolding [8], and our recent
demonstration of antioxidant dysfunction in SCADD fibroblasts
[23]. The relationship between abnormal FAO and secondary
mitochondrial dysfunction is likely multifactorial. Our studies
provide evidence of increased vulnerability to oxidative stress in
SCADD fibroblasts, with exacerbation by hyperthermia and
hypoglycemia. This exacerbation is of clinical relevance given that
individuals with ACADS gene spectrum e.g those identified on
newborn screening may remain asymptomatic until exposed to a
triggering illness. This exacerbation is also concordant with
mitochondrial import studies showing increased aggregation of
SCAD proteins with hyperthermia [8]. Given that both protein
aggregation and ROS production are aggravated by hyperthermia,
this further highlights the interrelationship between these two
mechanisms. The resulting oxidative imbalance from increased
ROS production and from antioxidant dysfunction [23] may
thereby exceed a subclinical threshold in affected individuals, giving
rise to clinical disease. The results of our studies are therefore
concordant with our hypothesis of increased vulnerability to
oxidative stress in the pathogenetic mechanism of SCADD. These
results also suggest an interweaving of pathogenetic mechanisms in
SCADD namelyincreased oxidative stress, with the previousstudies
which demonstrated antioxidant dysfunction [23] and protein
misfolding [8]. Furthermore, given that the SCAD protein is
nuclear-encoded, the demonstrated abnormalities in cultured skin
fibroblasts can be extrapolated to other cell types in the central and
peripheral nervous system and likely contribute to the neurological
and neuromuscular phenotypes of SCAD deficiency.
Figure 3. Effect of Bezafibrate (B) intervention (200 mmol/L, and 400 mmol/L in SCADD fibroblasts only) on menadione toxicity in
each FAO disorder under variable conditions. Logarithmic transformation followed by paired t-test compares menadione toxicity in each FAOD
with and without Bezafibrate, under each experimental condition. This figure shows that Bezafibrate significantly reduced menadione toxicity in the
SCAD and MTP/CPT2 deficient patient fibroblasts only, under all 4 experimental conditions (Table S5).
doi:10.1371/journal.pone.0017534.g003
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prior to the manifestation of clinical symptoms. This may explain
the discrepancy between the frequency of common SCAD
variations in the general population, and the prevalence of
clinically manifest SCADD. The vulnerability to oxidative stress
appears to be independent of the ACADS genotype, concordant
with previous reports of inconsistent genotype-phenotype correla-
tions [1,27]. A further example is the contrasting clinical
phenotypes of c.625G.A homozygosity which may be explained
by our recent description of decreased SOD2 expression in the
affected patient vs ‘asymptomatic control’ fibroblasts [23]. In
addition, exogenous stressors, such as hypoglycemia and fever,
may influence the clinical phenotype. Oxidative stress with
hydrogen peroxide, under heat stress, has been shown to impair
the heat stress response (HSP40/HSP70), delay unfolded protein
recovery and enhance loss of mitochondrial membrane potential
[28].
In mitochondrial Complex I deficiency with the cardiomyop-
athy and cataracts phenotype, it has been proposed that significant
induction of SOD2 may result from a temporarily much elevated
superoxide production rate in the presence of an abnormally
reduced redox state, as occurs in anoxia reperfusion injury [29].
Superoxide specifically attacks (4Fe-4S) centres in Complex I and
II resulting in release of free iron in mitochondria and cytosol
[30,31], which generates excessive OH
2 [32]. This could be the
mechanism in our SCADD fibroblasts, with exacerbation by heat
stress due to protein unfolding [8].
Oxidative stress is likely to trigger pro-apoptotic signaling
cascades [33]. Of the 7 glutathione peroxidases in mammals,
GPx4 is specific for phospholipid hydroperoxides in membranes,
and is shown to be significant for neuronal survival [33]. GPx4
senses and translates oxidative stress into a 12/15-lipoxygenase
dependent- and apoptosis-inducing factor-mediated cell death
pathway. In GPx4-knockout cells, lipid peroxidative injury was the
Figure 4. Effect of Antioxidant (AO) intervention on menadione toxicity in each FAO disorder under variable conditions. Logarithmic
transformation followed by paired t-test compares menadione toxicity in each FAOD with and without antioxidants, under each experimental
condition. This figure shows that antioxidants significantly increased survival time in the SCADD and CPT2/MTPD patient fibroblasts under all 4
conditions, and in the MCADD fibroblasts only at 37u with/without glucose (Table S6).
doi:10.1371/journal.pone.0017534.g004
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Vitamin E. Vitamins E and C have been reported to neutralize
free radicals [34]. We evaluated these effects at physiological
plasma concentrations. NAC has ROS scavenging actions, but is
also a precursor for glutathione synthesis, and thus essential for the
effects of GPx [35].
Intervention with Bezafibrate resulted in significant improve-
ment in viability only in the SCADD and CPT2/MTPD patient
cell lines under all 4 experimental conditions (Table S5). The
antioxidants significantly improved viability not only in the
SCADD and CPT2/MTPD cells, but also in the MCADD cells
at 37uC (Table S6). NAC however, was significantly effective in
improving viability in all patient cell lines under all 4 experimental
conditions , as well as the normal controls under 3 of the
experimental conditions at 0.5 mM, and in all 4 experimental
conditions at 5.0 mM (Table S7). In a Bonferroni comparison, the
effect of NAC 0.5 or 5 mM was significantly more effective in
improving cellular viability than AO or Bezafibrate under all
experimental conditions in the SCADD cell lines, p,0.001
(Tables S8, S9). This suggests that in SCADD cells, NAC has
more extensive antioxidant actions than vitamin C and E or
Bezafibrate. In the other cell lines, this difference in effect was less
consistent (Tables S8, S9).
The mechanism for Bezafibrate reduction of oxidative stress is
uncertain. Bezafibrate increases Complex I, III and IV enzyme
activities in control cells and significantly increases activity of
deficient RC complexes in certain RC deficient cells [36]. As EMA
may interfere with Complexes I and III, leading to ROS
generation, Bezafibrate may counteract, in part, these effects.
Whether Bezafibrate restores short-chain FAO requires further
studies.
The association between accumulated MCADD metabolites
and oxidative stress has been investigated. In rat brain, octanoic
and decanoic acids were shown to uncouple mitochondrial
Figure 5. Effect of N-acetyl-cysteine (NAC, 0.5 and 5 mmol/L) intervention on menadione toxicity in each FAO disorder under
variable conditions. Logarithmic transformation followed by paired t-test compares menadione toxicity in each FAOD with and without NAC,
under each experimental condition. This figure shows that NAC at both concentrations was significantly effective for SCADD, CPT2/MTPD, MCADD
patient fibroblasts under all experimental conditions. In the control fibroblasts, NAC at 5 mmol/L was effective under all experimental conditions.
doi:10.1371/journal.pone.0017534.g005
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release, increase lipid and protein oxidation damage and decrease
GSH levels [37,38]. Our small number of MCADD patient
fibroblasts survived significantly longer compared to 625G/G and
625G/A controls only at 37uC and in glucose-containing medium,
p,0.05 (Table S3). With the addition of high temperature and/or
glucose deprivation however, the MCADD cells were as sensitive
to menadione-induced toxicity as these control cells, p.0.05.
Furthermore, the MCADD fibroblasts were not significantly
different to the 625A/A controls under all four experimental
conditions. Therefore the MCADD fibroblasts did not appear to
have a similar degree of risk for increased vulnerability to oxidative
stress as seen in the SCADD and TFP/LCHADD fibroblasts.
Long-chain defect fibroblasts were more vulnerable to oxidative
stress, comparable to the SCADD patient fibroblasts, p.0.05
(Fig. 1, Table S3). This may be attributable to the accumulation of
palmitoyl-CoA and palmitoylcarnitine shown to have detergent
properties on isolated canine myocytic sarcolemmal membranes
and to potentiate ROS-induced lipid membrane peroxidative
injury in ischemia [39]. Further, long-chain acyl-CoA’s are potent
inhibitors of mitochondrial adenine nucleotide transporter (ANT1)
[40], which catalyzes exchange of ADP and ATP across the inner
mitochondrial membrane [41] and is the overall rate-limiting step
in oxidative phosphorylation [42]. Inhibition of ANT1 would lead
to increased ROS.
In conclusion, there appear to be multifactorial mechanisms
involved in the pathophysiology of clinical disease in SCAD
deficiency including intrinsic factors which predispose to vulner-
ability to oxidative stress and protein unfolding, as well as
exogenous stressors such as elevated temperature and hypoglyce-
mia. Certain of these factors may also contribute to the
pathophysiology of long-chain FAODs. The reversal of cellular
toxicity in vitro with antioxidants and bezafibrate supports the role
of these agents in maintaining mitochondrial homeostasis. We
advocate rigorous management of fever in SCADD patients,
avoidance of adverse conditions such as fasting, and prompt rescue
during a catabolic crisis. Antioxidants and Bezafibrate may prove
to be useful therapeutic agents for the prevention and amelioration
of the neurological morbidity seen in SCAD deficiency.
Supporting Information
Table S1 Summary of short-chain acyl-CoA dehydroge-
nase deficiency (SCADD), medium-chain acyl-CoA de-
hydrogenase deficiency (MCADD), carnitine palmitoyl-
transferase 2 deficiency (CPT2D) and mitochondrial
trifunctional protein deficiency (MTPD) patient and
control data under the 4 experimental conditions.
(PPT)
Table S2 Summary of subgroup analysis with Bonfer-
roni’s Multiple Comparison test of short-chain acyl-CoA
dehydrogenase deficiency (SCADD) under each experi-
mental condition.
(PPT)
Table S3 Summary of subgroup analysis with Bonfer-
roni’s Multiple Comparison test under each experimen-
tal condition.
(PPT)
Table S4 Summary of menadione toxicity in the 4
SCADD patient genotypes.
(PPT)
Table S5 Effect of Bezafibrate intervention (200 and
400 mmol/L in SCADD fibroblasts only) on menadione
toxicity in each FAO disorder under variable conditions.
(PPT)
Table S6 Effect of Antioxidant intervention on menadi-
one toxicity in each FAO disorder under variable
conditions.
(PPT)
Table S7 Effect of N-acetyl-cysteine (NAC, 0.5 and
5 mmol/L) intervention on menadione toxicity in each
FAO disorder under variable conditions.
(PPT)
Table S8 Effect of N-acetyl-cysteine (NAC, 0.5 and
5 mmol/L) intervention on menadione toxicity in each
FAO disorder and control lines under variable condi-
tions, compared to AO.
(PPT)
Table S9 Effect of N-acetyl-cysteine (NAC, 0.5 and
5 mmol/L) intervention on menadione toxicity in each
FAO disorder and control lines under variable condi-
tions, compared to Bezafibrate.
(PPT)
Figure S1 Menadione toxicity assay with rescue in
SCADD. Rescue of SCADD (n=11) from hypoglycemia and
hyperthermia with glucose administration and normothermia,
respectively, compared to SCADD cells with menadione toxicity
at physiological conditions. Paired t-tests indicated by errors bars
and p-values. This figure shows that rescue with glucose
administration increased survival by 1.56, compared to 3.16
increase in survival of SCADD cells rescued with normothermia.
At 39uC, rescue with glucose and normothermia increased survival
by 2.96, compared to glucose rescue alone, 1.36.
(TIF)
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